Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The big money won't be made until cannabis products are legal in a lot more countries. The demand is definitely there.
This is not an idea but all I got to say is the whole MJ sector sucks! I made an investment in this sector of a dozen or so stocks a couple of years ago and they are all at or near their all time lows. FAN F**KING TASTIC sector. Biggest buncha hype I've ever seen.
Anybody got any bright F$x*#n ideas
Absolutely bottomless right now
LOL! ...and that was a Good Move?
FDA fawked the sector it will be back...Reverse mergers and custodianship plays with tight floats
TANKED. Glad I cut off an arm to save a leg. I am now loaded in PTOTF.
1.00 it is...FDA fawkes this sector for now
Moving on to a different sector. Good luck.
Quite resilient today compared to most of the general sector.
Not really an article - corporate funded puff piece. Not sure those ever really help anything.
~yanqui
Elixinol Global to Present at Upcoming U.S. Investor Conferences
Elixinol Global Limited (Elixinol Globalor the Company) (ASX:EXL; OTCQX:ELLXF),a global company operating in the industrial hemp and emerging medicinal cannabis sectors, is attending the following investor conferences in October 2019.
Canaccord Genuity US Cannabis SymposiumWhen: Thursday, 3 October 2019 Where: Sheraton Centre – Toronto Presentation:1x1 and small group meetings
Alliance Global Partners Consumer Cannabis Conference When: Thursday, 3 October 2019 Where: Pierre Hotel – New York CityPresentation:1x1 and small group meetings
For more information about the conferences or to schedule a one-on-one meeting with Elixinol Global’s management, please contact your respective conference representative
Ron DufficyChief Financial Officerron.dufficy@elixinolglobal.com
About Elixinol GlobalElixinol Global Limited (ASX:EXL; OTCQX:ELLXF) is a global leader in the cannabis industry, selling hemp-derived CBD dietary supplements, hemp food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products.
Elixinol Global’s businesses include:
* Elixinol LLC (Elixinol), a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;
* Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products; and
* Nunyara Pharma Pty Ltd (Nunyara), founded in 2014 to participate in the emerging Australian medicinal cannabis market. Nunyara holds a manufacturing licence and its application for cultivation to the Office of Drug Control is currently pending approval.
See more at www.elixinolglobal.com
Check out the "U.S. Years of Cash Remaining" graph
https://grizzle.com/cannabis-industry-mass-extinction/?tl_inbound=1&tl_target_all=1&tl_period_type=3&ck_subscriber_id=432515143&fbclid=IwAR0hjMCk_IbyHi4n_835wZLYFEBNB6wePg_FqnmQH89JVRd-VW5jW8hdigk
I've got it on the watchlist, hope to be in it before it takes off again.
A crack in the armor toward legal weed in Oz: https://www.cnbc.com/2019/09/25/australias-capital-city-legalizes-marijuana.html
I think the gap should be closed now
Weed 5 on CNN this Sunday evening. I get the sense quality of the CBD supply chain maybe the issue - which is good for ELLXF and their brand.
insert-text-here
So far that gap is acting as support..
Elixinol signs exclusive distribution agreement for Finland
insert-text-here
"The exclusive distribution agreement with Harmonia Life follows Elixinol Global’s other recently
announced exclusive distribution arrangements for Benelux and Switzerland, Germany, United
Kingdom and New Zealand and is in line with Elixinol Global’s growth strategy to establish distribution
arrangements in targeted locations across various channels to leverage the significant long term
opportunities within the global hemp and cannabis market."
insert-text-here
Very close, might as well fill the darn thing:)
Amy Abernethy recently announced on Twitter that:
"[FDA] is expediting its work to address the many questions about cannabidiol (CBD). This is an important national issue with public health impact, & an important topic for American hemp farmers and many other shareholders.”
insert-text-here
Link didn’t work for me.
CBD Article:https://www.benzinga.com/markets/cannabis/19/09/14466329/the-who-what-when-where-and-why-of-cbd-nonprofit-releases-results-of-wide-ranging-survey" rel="nofollow" target="_blank" >insert-text-here
The Senate Appropriations Committee approved the $23.1 billion agriculture spending bill on Sept. 19. It now heads to the Senate floor for debate.
If approved, the FDA would have 120 days to adopt an enforcement discretion policy. The agency would also have to provide Congress with an update of its progress after 90 days.
insert-text-here
Is Elixinol Global (ASX:EXL) Using Debt Sensibly?
https://finance.yahoo.com/news/elixinol-global-asx-exl-using-022747285.html
Now available in South Africa:
https://elixinol.co.za/?fbclid=IwAR0VS6R3msYd_7wx2NsDhlHaNZ4a423e1wvwTwcj5i8CahqEGrz2g_KZSP4
Agree, I think around 1.25 there's a gap that might get tested and or filled, then this resets..
Not only that, but telling a group of people who pay for your recommendations to "sell at the market" sounds like the Miller's goal was manipulating the market. Is he trading against his recommendations? Was he short going into his alert? I bet he was. Sounds... unprofessional
Agree on everything. Elixinol has very large variety of SKUs out there including skin line and topicals.. also they have very wide presence worldwide and top two well known names in hemp industry on their team. Benhaim and Beckerman.
That to be said, yes, I would probably put more $ into marketing and make products more appealing to customers.
Otherwise it's all good imo
Mid to low 1s = Big time buying opportunity, imo
GLTA
GW
Thinking about adding. When the FDA gets involved, product quality will be very important. The highest quality products will be approved.
"The future of Elixinol is so exciting for me. We have finally reached a scale and maturity where we have farming, production, formulas, trusted branding, great relationships, a superb management team, excellent systems and a plethora of opportunities at our doorstep we are capable of meeting through our quality control systems and growth capacity. For now, it is all about the execution of our vision: to provide the best, highest quality hemp products to the market, via mainstream channels, through our trusted brand, based on science and technology, globally. Elixinol is and will continue to be a leading global hemp CBD brand."
insert-text-here
Mitch McConnell Tells FDA To Clear A Path For CBD Products Though Spending Bill Directive: insert-text-here
Response to Greg Miller:
1 - ELLXF doesn't sell high dose or low dose CBD. They sell CBD which you then dose yourself as high or low as you want. So this comment is invalid.
2 - It is true they don't sell isolates currently. Thought I think they will be bring out Broad Spectrum CBD down the road (i.e. no THC) along with their Full Spectrum CBD. I think ELLXF thinks that Full Spectrum is best due to the entourage effect. However, maybe the Broad Spectrum is good if you are concerned about drug tests etc. I would only use Full Spectrum. So this point doesn't concern me.
3 - He says they avoid some of the hottest products in the market like skin creams. A simple search of Elixinol's website would show CBD based topicals and HEMP line Sativa. So this is just false.
4 - Price: you pay for what you get. With Elixinol you get the highest quality throughout the process. So if you want cheaper, and most likely shittier products - go for it. However, I think alot of those products may soon face a regulatory backlash that ELLXF will avoid. Whether it is do to with farming practices (think Hemp Authority), or testing of how much CBD is actually in a product, or heavy metals etc - Elixinol will distinguish itself by the lack of regulatory interference. That's part of Brand Building.
5 - He makes a big assumption that the FDA will full y approve CDB in Food + Beverages. I think these are the areas with the most risk - due to drugs being in the food supply.
6 - Branding. I do agree that Elixinol's branding could connect more emotionally. I think this an area that they maybe working on. It cant be simply a science based lift. Once people accept CBD - emotionality is the connector.
7 - I also disagree with his negativity about international markets. I think this is good risk management (when faced with the Feds) and will pay-off down the line.
8 - Pet Releaf - it's good to have more revenue - provides liquidity going forward. Which I think they will also get with the increased production capacity in Colorado + the raw hemp they have secured + the inventory build-up. Now they just need to ship and market it. That will provide the revenue to continue expansion.
Who? Cannabis Investor's?
Do they have a website?
Today the mm’s covered a lot of short shares against their large short positions, thanks to the baseless article that they planted through their buddy-author. Soon they will stop algo-ing the stock down.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |